Similar articles

• Immunotherapy with a ragweed vaccine.

  Simons FE, HayGlass KT. Simons FE, et al. N Engl J Med. 2007 Jan 4;356(1):86-7; author reply 87. N Engl J Med. 2007. PMID: 17205611 No abstract available.
• Immunotherapy with a ragweed-toll-like receptor 9 agonist vaccine for allergic rhinitis.

  Creticos PS, Schroeder JT, Hamilton RG, Balcer-Whaley SL, Khattignavong AP, Lindblad R, Li H, Coffman R, Seyfert V, Eiden JJ, Broide D; Immune Tolerance Network Group. Creticos PS, et al. N Engl J Med. 2006 Oct 5;355(14):1445-55. doi: 10.1056/NEJMoa052916. N Engl J Med. 2006. PMID: 17021320 Clinical Trial.
• Amb a 1-immunostimulatory oligodeoxynucleotide conjugate immunotherapy decreases the nasal inflammatory response.

  Tulic MK, Fiset PO, Christodoulopoulos P, Vaillancourt P, Desrosiers M, Lavigne F, Eiden J, Hamid Q. Tulic MK, et al. J Allergy Clin Immunol. 2004 Feb;113(2):235-41. doi: 10.1016/j.jaci.2003.11.001. J Allergy Clin Immunol. 2004. PMID: 14767435 Clinical Trial.
• Weed pollen allergens.

  Mohapatra SS, Lockey RF, Polo F. Mohapatra SS, et al. Clin Allergy Immunol. 2008;21:127-39. Clin Allergy Immunol. 2008. PMID: 18828502 Review. No abstract available.
• Genetic engineering of pollen allergens for hayfever immunotherapy.

  Bhalla PL. Bhalla PL. Expert Rev Vaccines. 2003 Feb;2(1):75-84. doi: 10.1586/14760584.2.1.75. Expert Rev Vaccines. 2003. PMID: 12901599 Review.